Leading Biotechnology Company Picks ValGenesis's Offering to Manage Validation Process

Paperless validation enables life-transforming medicines at a faster pace to patients with serious diseases. Made up of scientists, industry experts, Nobel Laureates and members of the National Academy of Sciences, this leading biotechnology company consistently pushes the boundaries of scientific excellence and discovery in areas such as...

Paperless validation enables life-transforming medicines at a faster pace to patients with serious diseases.

Made up of scientists, industry experts, Nobel Laureates and members of the National Academy of Sciences, this leading biotechnology company consistently pushes the boundaries of scientific excellence and discovery in areas such as ophthalmology, oncology, inflammation and immunology, rare and infectious diseases, and pain management. The company’s industry-leading research and development engine allows it to discover therapies that could have a profound impact on patient health. In addition, it develops all potential drug candidates from within its own labs.

The company’s core capabilities for target discovery and validation are enabled by a series of inventive technologies that accelerate, improve and disrupt the traditional drug discovery and development process. Collectively, they represent some of the most valuable biotechnologies ever created and aid the company’s efforts to continuously accelerate the average timeline from discovery to drug approval—ultimately allowing it to expedite treatment to patients around the world.

Recognizing that traditional, manual, paper-based validation processes are costly and inefficient, the company selected ValGenesis Enterprise VLMS—an electronic, paperless solution that well meets its lifecycle validation needs. With ValGenesis Enterprise VLMS, the company will significantly reduce validation cycle time, gain a higher standard of data integrity, improve its regulatory compliance process, and gain a holistic view of real-time validation status across its regulated systems, thereby improving the quality and speed of the entire process.

“This is another feather in our cap and a testament to the solution we offer biotechnology companies, helping in their endeavor of pushing the boundaries of scientific excellence and discovery,” says Narayan Raj, Vice President of ValGenesis Inc., “There is a huge movement in the life science industry to eliminate the inefficiencies and delays that have plagued the validation process. ValGenesis is happy to offer a robust enterprise-class solution to help these companies automate their validation processes.”

Further information:

Althea D’Sylva, ValGenesis Communications, +1 510 648 3646 Ex. 1018,
203924@email4pr.com

About ValGenesis

ValGenesis, Inc. is the inventor of an innovative software platform serving as the foundation for managing compliance-based validation activities in Life Science companies. ValGenesis, Inc. provides the first enterprise application that manages the corporate validation lifecycle process. As the only system for managing validation execution and approval 100% electronically, ValGenesis was selected by an industry peer review committee to receive the Parenteral Drug Association (PDA) New Innovative Technology Award. ValGenesis solutions are fully compliant with U.S. FDA 21 CFR Part 11 and Annex 11 requirements.

For more information, visit http://www.valgenesis.com.

Source: www.valgenesis.com